Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.
about
Strategic biomarkers for drug development in treating rare diseases and diseases in neonates and infantsPharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study dataA re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data.Commentary: A Myriad Aberrations on Information of Ontogeny of Drug Metabolizing Enzymes in the Pediatric Population: An Obstacle for Personalizing Drug Therapy in the Pediatric PopulationA longitudinal study of urinary phthalate excretion in 58 full-term and 67 preterm infants from birth through 14 monthsPhysiologically based pharmacokinetic modeling and simulation in pediatric drug developmentDelayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections.Developmental and pediatric pharmacogenomics.Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents.Metabolism of oxycodone in human hepatocytes from different age groups and prediction of hepatic plasma clearance.Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs.Review and analysis of inhalation dosimetry methods for application to children's risk assessment.Computational pharmacokinetics during developmental windows of susceptibility.Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and ChildrenSummary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group.Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling.A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepamPopulation pharmacokinetics of oseltamivir: pediatrics through geriatrics.Modeling approaches for estimating the dosimetry of inhaled toxicants in children.Exposure to chemical cocktails before or after conception--- the effect of timing on ovarian development.Protein binding predictions in infantsFactors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and AdultsMaternal 3-methylcrotonyl-coenzyme A carboxylase deficiency with elevated 3-hydroxyisovalerylcarnitine in breast milk.Evaluation of a morphine maturation model for the prediction of morphine clearance in children: how accurate is the predictive performance of the model?Prediction of drug clearance in children 3 months and younger: an allometric approach.My child is unique; the pharmacokinetics are universal.Allometric extrapolation of factors VII, VIII and IX clearance in children from adults.Clinical implications of the transversus abdominis plane block in pediatric anesthesia.Clinical pharmacology of furosemide in neonates: a review.Pediatric drug development: formulation considerations.Prediction of glucuronidated drug clearance in pediatrics (≤5 years): An allometric approach.Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?Prediction of drug clearance in children: an evaluation of the predictive performance of several models.Infant spinal anesthesia: Do girls need a larger dose of local anesthetic?Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling.Prediction of Clearance in Neonates and Infants (≤ 3 Months of Age) for Drugs That Are Glucuronidated: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling.Approaches to acrylamide physiologically based toxicokinetic modeling for exploring child-adult dosimetry differences.Prediction of drug clearance in children from adults: a comparison of several allometric methods.Lactation stage influences drug milk-to-serum values and neonatal exposure risk.Guidance on the risk assessment of substances present in food intended for infants below 16 weeks of age
P2860
Q27024346-706D8636-2E82-40EA-A988-62897F5B7BA3Q30652267-0B53F501-6C95-43F1-93E9-6CF5542220A8Q30786488-4B815102-EDEC-4E07-A8BF-0D0F45373BADQ33604857-34D5F0F2-932C-428C-B3C8-E4E8ED48284BQ34131545-057BB699-20F5-4C13-A6D2-6389865E8A9EQ34658074-2A4E5501-5DD4-471C-9F65-C63A3DBC9A31Q34807224-86CD34B1-4953-44F5-B4CC-5B242660A5C3Q35116112-85A316B4-962B-43CB-A4BF-11C9B4AB606CQ35624622-7997990D-7BFF-4AE0-80BC-5686A01FA586Q35653564-815136F7-D43A-4AC0-8BCA-EA1A52F7A40EQ35827012-64D69F3A-A784-40C9-BA01-3756D0A1C21CQ36131290-D4CE562D-4B6B-48AB-B2B5-7B18E66557FAQ36195215-9B31760C-F32F-417C-A9FE-2A6C3484F450Q36322918-7A032A3C-3D89-4838-99FB-242A19B10069Q36501845-BB4292F7-285D-4491-BC52-BBB3FE57FEBDQ36571794-8A4A68AC-6B2F-4A39-97E5-88AF04BE8E59Q36910537-1018A144-AB29-4010-9D48-D938F9AA519BQ37036527-FB4D3D3E-7879-45FC-9F57-567B957C3F37Q37039742-5C5E26D2-73D3-42E9-B3CF-973BD024F39CQ37064622-6DD16838-E2FA-4D20-86BF-39B3DE16F79AQ37361786-5CE62B81-99DD-49E1-90D1-DD4F91BC9C7AQ37378093-50B37F0E-D7BA-46EA-908F-C77C19F3CE4BQ37525659-2B099B31-B472-4624-84B2-C92C5E44D6BDQ37818515-8F7785A2-ED30-41F0-A80E-930933102555Q37854677-AA43D5B7-5FAD-4E46-A405-7329A83E365BQ37973872-4E86858E-2574-4B8D-9ADB-CB49B5F5F3E7Q38011809-6AA68DF1-CEFB-4A46-A209-C00B6F1FF9FCQ38029717-40A0F492-E71A-4D2B-AD2B-6C992008990DQ38166237-BA51643D-F66C-41A2-9C36-6D1323EAB9E2Q38183868-168D4F9A-7653-4C01-8F0B-CEA05261AB04Q38187348-00BE7374-6394-4656-9011-967BF3F5281BQ38238947-79141B9D-E858-4E68-A59F-40A0BDAE6A17Q38256006-0A36FACA-6F52-4EBE-BA0C-DF4408DC1C2CQ38620848-D3AAF40D-1118-4065-8714-892A74BD5230Q38857191-BF9A94FC-C0D1-45B3-A213-CBB137AF1C05Q38972571-53FC41C2-A9DA-4FD5-9521-13DA2749A18AQ40148266-5FF74603-57A6-49E6-8D2A-AF68F07F2E19Q42758445-74121746-7670-40C1-A2CD-BB4F698413CCQ43067224-23F77B6C-6425-43D9-879B-1CE5849776AEQ47159532-855FF46B-2621-4923-A308-B3B8869CEF71
P2860
Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.
@ast
Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.
@en
Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.
@nl
type
label
Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.
@ast
Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.
@en
Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.
@nl
prefLabel
Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.
@ast
Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.
@en
Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.
@nl
P1476
Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.
@en
P2093
Jane Alcorn
Patrick J McNamara
P304
P356
10.2165/00003088-200241130-00005
P577
2002-01-01T00:00:00Z
P6179
1011381931